FDA denies Lilly appeal
The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
